登陆美股近十年之际,百济神州首次在业绩快报中给出了2025年经营利润为正的预计。其2月28日公布的2024年业绩快报显示,公司在报告期内实现营收272.14亿元,同比增长56.2%,净亏损额也收窄至49.78亿元。两款自研产品BTK抑制剂泽布替尼(商品名为百悦泽)和PD-1肿瘤药替雷利珠单抗(商品名为百泽安)仍是公司营收主力。 亏损约50亿元 百济神州的亏损还在继续,据业绩快报,报告期内实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.